Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6516159 | 0.81 | ALDH1A1 (0.47) | KDM4EALDH1A1RAB9AGAAPOLB | |
| SCHEMBL19086810 | 0.79 | KDM4E (0.50) | KDM4EALDH1A1KAT2BRAB9AGAA | |
| SCHEMBL19207766 | 0.78 | KDM4E (0.46) | KDM4EALDH1A1KAT2BPOLBNPC1 | |
| SCHEMBL31052471 | 0.76 | POLB (0.45) | KDM4EALDH1A1RAB9APOLBTSHR | |
| SCHEMBL9696618 | 0.76 | KDM4E (0.57) | KDM4EALDH1A1RAB9AGAAPOLB | |
| SCHEMBL17980904 | 0.76 | POLB (0.45) | KDM4EALDH1A1GAAPOLBLMNA | |
| SCHEMBL11686733 | 0.76 | POLB (0.47) | KDM4EALDH1A1GAAPOLBLMNA | |
| SCHEMBL8270927 | 0.75 | KDM4E (0.59) | KDM4EALDH1A1RAB9AGAAPOLB | |
| SCHEMBL11687804 | 0.74 | POLB (0.46) | KDM4EALDH1A1GAAPOLBLMNA | |
| SCHEMBL2338357 | 0.74 | POLB (0.49) | KDM4EALDH1A1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12358928-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240150376-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| CN-114437105-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-109071504-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-03-08 | — | — | CN | disclosed |
| US-20200317691-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317691-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-10604535-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-01-25 | — | — | US | disclosed |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-01-25 | — | — | US | disclosed |
| US-9815850-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815850-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815850-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | KDM4E 2322/4885ALDH1A1 3854/4885KAT2B 961/4885 |
| US-20200317691-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | KDM4E 1466/4885ALDH1A1 4405/4885KAT2B 709/4885 |
| US-20240150376-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | KDM4E 1466/4885ALDH1A1 4405/4885KAT2B 709/4885 |
| US-12358928-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | KDM4E 1466/4885ALDH1A1 4405/4885KAT2B 709/4885 |
| US-20230043400-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | KDM4E 1466/4885ALDH1A1 4405/4885KAT2B 709/4885 |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | KDM4E 1466/4885ALDH1A1 4405/4885KAT2B 709/4885 |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | KDM4E 1466/4885ALDH1A1 4405/4885KAT2B 709/4885 |
| US-10604535-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | KDM4E 1466/4885ALDH1A1 4405/4885KAT2B 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.